Sign Up for Free!

Continue Analyzing the page and more.

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

Biora Therapeutics Inc logo
BIOR

Biora Therapeutics Inc

MaveScore 35 Low model confidence
Last Price US$0.22 As of Jan 23, 2026
Market Cap US$6.7m Company size context
7D Performance 0.00% Past 7 days
1Y Performance -68.57% Past 12 months
Model Rating
Historical model output for research review

Fundamental data date

Dec 31, 2024

532 days old

Market price date

Jan 23, 2026

144 days old

Coverage

16/16

No missing model inputs

Data quality

Review

Partial or delayed snapshot

Transparent research score

Why the model scores this stock

MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

MaveScore 35 Low confidence

Stored data quality

Freshness and coverage checks

Stored company inputs are available, but some dates or model fields are older or incomplete.

16/16 Partial or delayed snapshot

Quality

Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.

12/35 Weak

Financial Strength

Financial strength rewards durable profitability, margins, and positive free cash flow.

10/25 Weak

Valuation Support

Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.

7/15 Weak

Momentum

Momentum highlights research candidates with supportive 3-month and 6-month price regimes.

5/15 Weak

Shareholder Alignment

Shareholder alignment rewards less dilutive share behavior and enough size for liquid research coverage.

1/10 Weak

Positive model output

More live company inputs are needed before positive research signals can be surfaced.

Research risks to review

  • Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.
  • Financial strength rewards durable profitability, margins, and positive free cash flow.
  • Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.

MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting.

Dashboard Funda..tals Deep..lue Prediction Screener Map

Biora Therapeutics Inc Overview

Industry: Biotechnology

Sector: Healthcare

Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and Systemic oral delivery platform for oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.

Biora Therapeutics Inc is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.

Score

Price History & Performance

Review Biora Therapeutics Inc in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.

Recent News



Biora Therapeutics Inc Competitors

Biora Therapeutics Inc operates in the Biotechnology industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.

Earnings Per Share

EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.

Continue the analysis

Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.

View plans
Ticker Image

Biora Therapeutics Inc

US$0.22

US$6.7m

0.00%

-68.57%